Pharmaceutical Compositions for Preventing and Treating Th1 or Th2 mediated Immune Disease Comprising 4H3MC(4-Hydroxy-3-methoxycinnamaldehyde) as an Active Ingredient

a technology of th1 or th2mediated immune disease and active ingredient, which is applied in the direction of pharmaceutical delivery mechanism, medical preparations, edible oils/fats, etc., can solve the problems of undeveloped therapeutic agent against t-cell-mediated disease, which targets pkc, and the effect of 4h3mc, a cinnamic acid derivative, on the activation of t cells,

Inactive Publication Date: 2017-09-07
GWANGJU INST OF SCI & TECH
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These autoreactive lead to target organ and tissue damages, which are exaggerated by elevated T cell cytokines even after antigen clearance [2].
However, a therapeutic agent against T-cell-mediated disease, which targets PKC, has not yet been developed.
However, the effect of 4H3MC, a cinnamic acid derivative, on the activation of T cells, has not yet been found.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical Compositions for Preventing and Treating Th1 or Th2 mediated Immune Disease Comprising 4H3MC(4-Hydroxy-3-methoxycinnamaldehyde) as an Active Ingredient
  • Pharmaceutical Compositions for Preventing and Treating Th1 or Th2 mediated Immune Disease Comprising 4H3MC(4-Hydroxy-3-methoxycinnamaldehyde) as an Active Ingredient
  • Pharmaceutical Compositions for Preventing and Treating Th1 or Th2 mediated Immune Disease Comprising 4H3MC(4-Hydroxy-3-methoxycinnamaldehyde) as an Active Ingredient

Examples

Experimental program
Comparison scheme
Effect test

examples

[0051]Materials and Methods

[0052]Cell Culture

[0053]Jurkat T cells (ATCC, CRL-1651, Manassas, Va.) and Raji B cells (ATCC, CCL-86) were cultured in RPMI complete medium supplemented with 10% fetal bovine serum (FBS, AusGeneX, Santa Clara, Calif.) and PenStrep (Gibco-RBL). After written informed consent, human peripheral blood leukocytes (PBL) were isolated from healthy donors by a sedimentation method using dextran and Ficoll Amersham Biosciences, Piscataway, N.J.). All the cell lines and cells used in the present invention were cultured at 37° C. in a humidified incubator containing 5% CO2. All experiments using human peripheral blood leukocytes were approved by the Ethics Committee of the School of Life Sciences, GIST.

[0054]Reagents and Antibodies

[0055]4-Hydroxy-3-methoxycinnamaldehyde (4H3MC; PubChem CID: 5280536) and p-hydroxycinnamic acid (HCA; PubChem CID: 637542) with the purity over 99% were provided by Professor Seung-Ho Lee from Yeungnam University (Korea). For treatment in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
concentrationsaaaaaaaaaa
pHaaaaaaaaaa
Login to view more

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating Th1- or Th2-mediated disease, which comprises 4H3MC (4-hydroxy-3-methoxycinnamaldehyde) as an active ingredient. 4H3MC (4-hydroxy-3-methoxycinnamaldehyde) according to the present invention shows the effect of inhibiting T-cell activity without inducing T-cell death. Thus, 4H3MC (4-hydroxy-3-methoxycinnamaldehyde) according to the present invention can be developed into an effective therapeutic agent against Th1- or Th2-mediated disease, etc.

Description

BACKGROUND OF THE INVENTION[0001]Field of the Invention[0002]The present invention relates to a pharmaceutical composition for preventing or treating Th1- or Th2-mediated immune disease, which comprises 4H3MC (4-hydroxy-3-methoxycinnamaldehyde) as an active ingredient.DESCRIPTION OF THE RELATED ART[0003]T cell-mediated immune responses known as adaptive immunity develop antigen-specific T cells for eradiation of pathogens and malignant cells. In addition, T cell-mediated immune responses can also include atypical recognition of autoantigens, leading to autoimmune diseases [1]. These autoreactive lead to target organ and tissue damages, which are exaggerated by elevated T cell cytokines even after antigen clearance [2]. Thus, modulation of T cell responses is a central approach to develop autoimmune disease therapeutic agents.[0004]When T cells are stimulated by antigen-presenting cells, the T cells are activated and a signal is transmitted into the cells. In this process, protein ki...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/11A23L33/10A61K9/00
CPCA61K31/11A23V2002/00A23L33/10A61K9/0056A23D9/00A23L33/105Y02A50/30
Inventor JUN, CHANG-DUKAKBER, UROOSLEE, HYUN SU
Owner GWANGJU INST OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap